-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $91

Benzinga·11/17/2026 13:22:13
Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.